Results 131 to 140 of about 93,886 (309)

Mitochondria and the Actin Cytoskeleton in Neurodegeneration

Cytoskeleton, EarlyView.
ABSTRACT Mitochondrial dysfunction and cytoskeletal disorganization are widely recognized hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
Shivani Tuli, Preet Patel, Aneri Shethji, David Gau   +3 more
wiley   +1 more source

DPVis: Visual Analytics with Hidden Markov Models for Disease Progression Pathways

, 2020
Clinical researchers use disease progression models to understand patient status and characterize progression patterns from longitudinal health records.
Anand, Vibha,, Frohnert, Brigitte I.,, Ghosh, Soumya,, Kwon, Bum Chul,, Lund University., Lund University., Lundgren, Markus,, Ng, Kenney,, Severson, Kristen A.,, Sun, Zhaonan,   +9 more
core   +1 more source

Music therapy in Huntington’s disease: a protocol for a multi-center randomized controlled trial [PDF]

, 2016
Monique van Bruggen-Rufi, Annemieke Vink, Wilco P. Achterberg, Raymund A.C. Roos   +3 more
openalex   +1 more source

Differences in white matter detected by ex vivo 9.4T MRI are associated with axonal changes in the R6/1 model of Huntington’s Disease [PDF]

, 2023
Chiara Casella, Brian Kelly, Alvaro Murillo, B. Mills-Smith, Geoffrey Parker, Chris von Ruhland, Yasir Ahmed Syed, Vincent Dion, Anne Rosser, Claudia Metzler‐Baddeley, Derek K. Jones, Mariah J. Lelos   +11 more
openalex   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

A2A Adenosine Receptor Agonists With Last‐Step Enzymatic 18F‐Labelling Potential (Fluorinase) for Positron Emission Tomography (PET)

European Journal of Organic Chemistry, EarlyView.
This study exploits the comparable binding tolerances between the fluorinase enzyme and the A2A adenosine receptor towards the development of novel C‐2 functionalised 5′‐fluorodeoxy‐adenosine (FDA)‐based agonists with enzymatic 18F‐labelling capability for positron emission tomography (PET).
Nicolas Charalambous, Carina Schleidt, Rongfang Liu, Laura H. Heitman, Sergio Dall’Angelo, David O’Hagan, Phillip T. Lowe   +6 more
wiley   +1 more source

Embryos as Patients? Medical Provider Duties in the Age of CRISPR/Cas9 [PDF]

, 2017
The CRISPR/Cas9 genome engineering platform is the first method of gene editing that could potentially be used to treat genetic disorders in human embryos. No past therapies, genetic or otherwise, have been intended or used to treat disorders in existent
Powell, G. Edward, III
core   +1 more source

Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntington’s Disease [PDF]

, 2018
Christopher D. Rowley, Sarah J. Tabrizi, Rachael I. Scahill, Blair R. Leavitt, Raymund A.C. Roos, Alexandra Dürr, Nicholas A. Bock   +6 more
openalex   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

2008 Progress Report on Brain Research [PDF]

, 2008
Highlights new research on various disorders, nervous system injuries, neuroethics, neuroimmunology, pain, sense and body function, stem cells and neurogenesis, and thought and memory.
Eve Marder, Mahlon R. DeLong, Michael S. Gazzaniga, Thomas Wichmann   +3 more
core